Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $13.13

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has earned an average rating of "Buy" from the nine ratings firms that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $13.13.

A number of research firms have recently commented on CMPX. HC Wainwright restated a "buy" rating and issued a $24.00 price objective on shares of Compass Therapeutics in a research report on Monday, April 21st. Guggenheim cut their price objective on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Jefferies Financial Group lifted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, February 10th. D. Boral Capital reiterated a "buy" rating and set a $32.00 target price on shares of Compass Therapeutics in a research report on Monday, April 28th. Finally, Leerink Partners upgraded shares of Compass Therapeutics from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd.

Insider Transactions at Compass Therapeutics

In related news, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction on Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. This trade represents a 2,000.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Company insiders own 29.80% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its stake in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after acquiring an additional 12,917 shares in the last quarter. Independent Advisor Alliance purchased a new stake in Compass Therapeutics during the 4th quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics during the 4th quarter valued at about $27,000. Mariner LLC purchased a new stake in Compass Therapeutics during the 4th quarter valued at about $30,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Compass Therapeutics in the fourth quarter worth approximately $35,000. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Price Performance

Shares of CMPX traded up $0.02 during trading hours on Thursday, hitting $2.11. The company's stock had a trading volume of 662,949 shares, compared to its average volume of 922,864. The company has a market cap of $291.78 million, a price-to-earnings ratio of -5.70 and a beta of 1.40. The business has a 50 day simple moving average of $1.90 and a two-hundred day simple moving average of $2.12. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting the consensus estimate of ($0.12). Research analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.